Member Info for hunkymonkey

Agree with this 100%. I am critical of the bod currently, not because I don't believe in them or indeed the product. I'm critical because for what they've got, they should be doing so much better!

Away from this rns today, I find people like to assume and have conjecture about collaborations etc etc. People don't like dealing in the facts. So I didn't even realise when I posted last week about the slip in the African figures of £1.1mln to distort the accounting figures to show an upward trend. One thing I've learned over the weekend, it's not the first accounting anomoly there had been? There were others circa 2017/18. Interesting

Firstly get one thing straight, I'm not worried in the slightest. What people need to try and do is critique. Are the bod supporting the sh? Or indeed are they continuing to make the same mistakes? Lack of detail killed what could have been a good rns. Yet with the Russian distributor they can put targeted sales of $2mln!!?? What have the current sales been? No info! Future sales? No info? Pricing? No info! So what was the point of the rns other than, in reality, saying we've got additional r&d costs.

On the face of it it looks like a good rns, well in fact, yes it is. Building relationships with existing collaborations is a positive.

The issue lies with the same old same old here, lack of detail, lack of figures. How can investors or the market assess without detail. By their own admission, sales so far have been slow, but without scaled up figures, I'm afraid this rns is having little or no impact.

I've been taking about why there sp is at almost a company low, rather than just back slapping and blaming the mms or shorters or aliens. Here lies the issue, slow sales so far, increased revenue in the medium to long term with monthly fee rise, but r&d costs now to adapt there product. If people are looking for reasons why there sp is so v low, this rns explains it, low sales for the product, but then having r&d costs to develop and adapt the product.

It's for the above reason why the sp has been struggling of late and why I think a raise is coming

The problem with an extended bank loan is that it is a very expensive way of financing and ultimately could be detrimental to share holders in the long term.

The only way this would be viable, is if the bod were assured that a big contract was imminently about to be signed with an upfront payment. If not, just extending a bank loan, in hope, would only result in a bigger raise because of the higher rate of borrowing, whilst putting the company in a more vulnerable position in negotiations for the raise. It's a lose lose for lth in that instance

It's the equivalent of paying bills on your credit card, hoping that you hit a bonus to pay it off otherwise

£10mln in revenues by 2021 is nothing, as by then the products will have have had to move on. R&D will have to have increased to adapt to one of the quickest adapting industries there is.

Here's the real question, a very simple one. What do people actually think the net profit will be for last year? But then also assume Allenby figures are correct, on those years? Do you think that those net profits are going to provide enough capital to r&d costs? If not, then what?

Have to disagree, of course it matters. You can choose to ignore the facts or accept them. The reason why it matters, it massively affects the beautiful curvature of figures.

If you've been in long enough, you'll remember that most definitely that order slipped from 2018 to 2019. If that payment paperwork had not have been delayed. 2019 sales were appalling! And indeed 2018 were much better.

It matters because it shows instability in sales.

Now, that can be down to numerous factors, most likely, trying to get big order from collaborations and less focus on smaller distributors. But that one slip payment by 3wks changes the last 3 year figures dramatically. It shows whether the company is progressing with sales or not.

Side note here also. No doubt at all that 2019 was a good year, whenever any tech company goes ebitda +, it is a milestone.

Again, the new collaborations are an encouraging demonstration of starcom product.

My question is, isolate the revenue for 2019. I pose this question, how good was it really? Consider £1.1mln of that revenue came from a delayed deal from North Africa 2018. So assuming that the full amount was received in the 2019 accounting period, it distorts immensely either the 2018 or 2019 figures substantially.

Well, surely it's better to have a small piece of pie than none. There was absolutely no way they could have raised this kind of capital on a drug that financially crippled two companies. Fantastic deal, especially considering the plight that they were in.

Yes good luck to you also. Feeling good about my 1.21p buy now tbh. Pleased you never got tetchy about me mentioning the dreaded "rise" and had a reasoned discussion. You are a real credit to the BB

Well, good luck Cristal, I see how you've ended up having to average down. Not usually something I do, I actually prefer to average up. I'm still concerned about the impact of no large contract, which is why I only bought 266k. But there's enough here to suggest a good rise, certainly I think that we'll get an insight into eoy sales, which should provide a good rerate (hopefully) with our without a larger contract. Good luck all and thanks for the info

Thank you once again for taking the time last week, I've spent some time reading what you have put over the weekend and bought this afternoon. Only a feeler, let's see how the price goes from here........

Shock horror, it showed as a buy for a change!

I believe that this drop is a flash in the pan, providing investors understand what is going on. There were approximately 4.5mln shares issued. Over the past two trading days, I think that you can account for the 4.5mln shared based upon large round sells. My only slight concern, is I've not found a trade that balances of the shares that were issued, i.e a trade with 55 at the end. So i do believe that the consultant, must be about done for their selling. This assumes that not that many pi followed suit and jumped ship and sold large round numbers because they don't understand the difference between a Concultancy and investment firm

Because they are a consultency, not an investment company. They want the cash in the bank, don't look at it from an investment standpoint. Anyway, I think my initial comment (that was shot down) has proved to be correct with the continued high volume, round sells. To be honest, from a pi standpoint, it's better that they are selling now, as you don't want them offloading millions of shares inhibiting any future rises.

I suggested this yesterday and got battered down. Of course the consultants are selling, they are not investors they are a business wanting their cash!

I'm thinking that it is the consultant shares that were admitted being sold. Quite a few to go if that's the case

Genuinely thank you very much for this information, i really appreciate you taking the time. It's given me a lot of really useful information

Firstly, thank you for the compelling case and there were a few new names to me that I shall do my DD on.

But. Last year there was a delayed payment from an African company, I always get nervous with African deals, having been burnt in the past. That's another story.

So if that £1.1mln had have been paid on time, the last yrs revenues "should have been" £7.1mln, if all truth be told. So, by rights, a true reflection this year should surely be a target. That only keeps pace with last yr and to move forward, you need to exceed that figure. From all that I have read that seems to have been missed by many investors, or at least, I have got that wrong.

For me, right now, you jump too early, you could be stung next yr with a raise (I accept that's my opinion - not yours). But if you don't take the plunge and a contract lands. You're stuffed and have missed the boat.

You have got to love aim!

My opinion though on the

Sp2 thanks for the response. I got the q1 raise from myles, whom I believe, bought shares in a raise . Recently he suggested that they were good for cash until q1. Then looking historically, that seemed to fit. I also noted the new approvals of late, with Russia and airlines. All is very good indeed, but until that materialises on the bottom line, I don't see a reversal in sp. I've read a lot about, we should be this mcap or that. I like to like to look at why are they at X or y. Incidentally, with the recent new approvals, we simply don't know know paid for that, obviously vigorous tests were conducted (especially for the airline), so we simply don't know the current cash burn, but something to consider at least. I also noted that there was an overdraft facility that was drawn on, so would have needed paying

I do reiterate in the strongest terms, I like the tech, how it is being sold is my concern and how long will it be before before the they truly turn the corner. Could be tomorrow, could be longer, no one knows.

I've recently read back to the £1.1mln contract at the start of the year. This is interesting as it looks like it should have been in the previous year account, which would have made last year £7+mln for the year. As it's gone into this year's accounts, I would expect £10mln+ with the added funds from last year to make progress yoy in reality. Just something I noted

It's a massively transitioning sector and a hot market right now, which is why star has come onto my radar, the tech all these companies have at any one time has a short self life (like the padlock), so unless at each stage of development big contracts are signed, it's difficult to have the cashflow to develop yourself without the raise. This is what I note and what is stopping me from investing right. I wondered how rational holders respond to this?

The issue is, r&d developing bespoke products for relatively low sales. So because star have never landed anything significant, I mean multiple millions, they are caught in a perpetual cycle of not landing contracts, always having r&d costs, then having to capital raise to continue. It all changes with a big contract, but they are good for cash until q1 2020. So essentially this is a gamble now, the gamble is, can they land a big contract to give them to cash reserves they need Vs the inevitable raise should they not. For parity, there will be a huge rerate should they be successful.